Softwr

Healthcare · head to head

Paige vs VideaHealth

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
VideaHealth logo

VideaHealth

Dental

FDA-cleared AI for dental X-ray analysis

From
$399/month
Rated
-

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; VideaHealth not a standalone practice management system; requires integration with existing practice software
  • They diverge on capability: Paige covers Paige Prostate Detect, VideaHealth covers FDA-cleared AI detection.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and VideaHealth actually diverge.

Attributes where Paige and VideaHealth differ
AttributePaigeVideaHealth
Starting priceOn request$399/month
Pricing modelquotesubscription
PlatformsWeb, Cloud, On-premiseWeb
CategoryHealthcareDental
FoundedUnknown2022

Identical on both: free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in VideaHealth

  • FDA-cleared AI detection
  • Cavity detection
  • Bone loss analysis
  • Real-time results
  • Patient education tools
  • Dexis
  • Patterson Imaging
  • Carestream

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot VideaHealth
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot VideaHealth
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot VideaHealth
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot VideaHealth

VideaHealth

  • Diagnostic assistancenot Paige
  • Treatment planningnot Paige
  • Patient communicationnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

VideaHealth

  • Not a standalone practice management system; requires integration with existing practice software
  • Focuses only on imaging analysis; does not handle billing, scheduling, or patient records directly
  • Pricing not publicly disclosed

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

VideaHealth

$399/month
  • Practice$399/month
    • AI X-ray analysis
    • Real-time detection
    • Treatment insights
  • Enterprise$799/month
    • Multi-location
    • Advanced analytics
    • API access

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.

Choose VideaHealth if

  • You need fda-cleared ai detection.
  • You also want cavity detection.

Questions people ask

Is Paige or VideaHealth better?
Neither clearly leads. Paige starts at On request and VideaHealth at $399/month, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or VideaHealth?
Paige starts at On request and VideaHealth at $399/month.
Does Paige or VideaHealth run on more platforms?
Paige runs on Web, Cloud, On-premise. VideaHealth runs on Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what VideaHealth is typically brought in for.
What can Paige do that VideaHealth cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications. VideaHealth covers FDA-cleared AI detection, Cavity detection, Bone loss analysis, Real-time results.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

VideaHealth: What does VideaHealth detect in dental images?

VideaHealth's AI detects over 30 dental conditions on 2D radiographs to assist clinicians in diagnosis and treatment planning.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

VideaHealth: Is VideaHealth a standalone practice management system?

No. VideaHealth is an AI imaging platform that integrates with existing dental practice management systems, not a complete practice management solution.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

VideaHealth: Which practice management systems does VideaHealth work with?

VideaHealth integrates with Henry Schein One's Dentrix and Dentrix Ascend platforms. It is designed to work with approximately 90% of dental imaging systems.

Source
Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

VideaHealth: Who uses VideaHealth?

VideaHealth is used by major dental service organizations (DSOs) including Heartland Dental, 42 North Dental, and DentalCorp, as well as private dental practices.

Source
Share

Related pages

Other head to heads